Bibliography

Filters: First Letter Of Keyword is D  [Clear All Filters]
A B C [D] E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
Dyspnea
Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7). Abstract
Duplicate Publication as Topic
Wager E, Wiffen PJ. Ethical issues in preparing and publishing systematic reviews. J Evid Based Med. 2011;4(2):130-4.
Drug-Related Side Effects and Adverse Reactions
McCullough LB, Coverdale JH, Chervenak FA. Constructing a systematic review for argument-based clinical ethics literature: the example of concealed medications. J Med Philos. 2007;32(1):65-76. Abstract
Golder S, Loke Y, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol. 2008;61(5):440-8. Abstract
Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, et al. Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol. 2013;31(20):2580-5. Abstract
Basch E. Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance. Drug Saf. 2013;36(4):277-8.
Drug Utilization
Fattal J, Lehoux P. Health technology assessment use and dissemination by patient and consumer groups: why and how? Int J Technol Assess Health Care. 2008;24(4):473-80. Abstract
Drug Toxicity
Golder S, Loke Y. Search strategies to identify information on adverse effects: a systematic review. J Med Libr Assoc. 2009;97(2):84-92. Abstract
Golder S, Loke YK. Sources of information on adverse effects: a systematic review. Health Info Libr J. 2010;27(3):176-90. Abstract
Golder S, McIntosh HM, Loke Y. Identifying systematic reviews of the adverse effects of health care interventions. BMC Med Res Methodol. 2006;6(22). Abstract
Golder S, Loke YK, Bland M. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview. J Clin Epidemiol. 2010;63(10):1071-81. Abstract
Drug Therapy
Golder S, McIntosh HM, Loke Y. Identifying systematic reviews of the adverse effects of health care interventions. BMC Med Res Methodol. 2006;6(22). Abstract
Golder S, Loke Y. Search strategies to identify information on adverse effects: a systematic review. J Med Libr Assoc. 2009;97(2):84-92. Abstract
Brett Hauber A, Fairchild AO, Reed Johnson F. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature. Appl Health Econ Health Policy. 2013;11(4):319-29. Abstract
Ozieranski P, McKee M, King L. The politics of health technology assessment in Poland. Health Policy. 2012;108(2-3):178-93. Abstract
Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7:32. Abstract
Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy. 2012;108(2-3):167-77. Abstract
Drug Resistance, Bacterial
Golder S, Glanville J, Ginnelly L. Populating decision-analytic models: the feasibility and efficiency of database searching for individual parameters. Int J Technol Assess Health Care. 2005;21(3):305-11. Abstract
Drug Labeling
Basch E. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health. 2012;15(3):401-3.
Drug Industry
Breckenridge A, Woods K, Walley T. Medicines regulation and health technology assessment. Clin Pharmacol Ther. 2010;87(2):152-4. Abstract
Ozieranski P, McKee M, King L. The politics of health technology assessment in Poland. Health Policy. 2012;108(2-3):178-93. Abstract
Golder S, Loke YK, Bland M. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview. J Clin Epidemiol. 2010;63(10):1071-81. Abstract
Drug Evaluation
Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7:32. Abstract
Gelijns AC, Rigter H. Health care technology assessment in The Netherlands. Int J Technol Assess Health Care. 1990;6(1):157-63.
Drug Discovery
Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369(5):397-400.